- $99.43bn
- $118.21bn
- £31.38bn
- 92
- 66
- 99
- 98
REG - GlaxoSmithKline PLC - ViiV Healthcare announces FDA approval of Apretude
AnnouncementREG - GlaxoSmithKline PLC - Consumer Healthcare Chair Designate appointed
AnnouncementREG - GlaxoSmithKline PLC - Xevudy approved in Europe to treat COVID-19
AnnouncementREG - GlaxoSmithKline PLC - GSK/Sanofi COVID-19 vaccine booster & Ph3 update
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG-GlaxoSmithKline plc: Total Voting Rights
AnnouncementREG - JPMorgan Inv. Trusts - Ten Largest Investments
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSK Capital PLC - Publication of a Prospectus
AnnouncementREG - GlaxoSmithKline PLC - Medicago/GSK COVID-19 vaccine positive Ph3 data
AnnouncementREG - GlaxoSmithKline PLC - Sotrovimab retains its activity vs Omicron variant
AnnouncementREG - Allianz Glbl Inv - Top 10 Holdings
AnnouncementREG - GlaxoSmithKline PLC - Sotrovimab retains its activity vs Omicron variant
AnnouncementREG-GlaxoSmithKline plc: Total Voting Rights
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - GSK publishes provisional 2022 dividend dates
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - Nucala approved in Europe for more indications
AnnouncementREG - GlaxoSmithKline PLC - Block listing Interim Review
Announcement